 |
市場調査レポート
商品コード
1463388
マイコプラズマ検査の世界市場規模、シェア、成長分析、用途別、最終用途別 - 産業予測、2024～2031年Global Mycoplasma Testing Market Size, Share, Growth Analysis, By Application(Cell Line Testing, Virus Testing), By End-Use(Academic Research Institutes, Cell Banks) - Industry Forecast 2024-2031 |
||||||
| マイコプラズマ検査の世界市場規模、シェア、成長分析、用途別、最終用途別 - 産業予測、2024～2031年 |
|
出版日: 2024年04月12日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のマイコプラズマ検査の市場規模は、2022年に2億9,891万米ドルとなり、2023年の3億4,076万米ドルから、2031年までには9億7,204万米ドルに成長し、予測期間中（2024～2031年）にCAGR14％で成長する見通しです。
様々な状況においてマイコプラズマ汚染を特定し、回避するために、信頼でき、正確で、効果的な機器とサービスを提供することが、マイコプラズマ検査市場の目的です。この市場には、コンサルティング、検査、バリデーションなどのラボサービスに加え、機器、ソフトウェア、試薬、キット、検査などの幅広い商品が含まれます。マイコプラズマ検査市場は、バイオテクノロジー、製薬、学術研究、臨床診断など数多くの産業にサービスを提供しています。マイコプラズマ検査市場は、細胞ベースの治療やバイオ医薬品に対するニーズの高まり、マイコプラズマ汚染による潜在的な危険性や影響に対する意識の拡大、マイコプラズマ検査のための洗練された技術やプラットフォームのイントロダクションなど、複数の原因によって推進されています。さらに、マイコプラズマ検査に関する規制基準や規範の厳格化・標準化により、より信頼性が高く効果的な検査ソリューションへのニーズが高まっています。また、マイコプラズマ検査市場は、検査製品やサービスの高価格、検査プロトコルの調和と一貫性の欠如、マイコプラズマ検査のためのインフラと適格な労働力の不足など、多くの変動要因によって制約されています。また、マイコプラズマ検査の市場は、変化する消費者や規制当局の要求に応えるために、検査製品やサービスの継続的な革新と強化が求められるなど、多くの障害と戦わなければなりません。さらに、他の汚染物質との交差反応性、偽陽性や偽陰性の結果、マイコプラズマ株の遺伝的変異性や適応の可能性などの問題にも対処する必要があります。
目次
エグゼクティブサマリー
- 市場概要
- 運命の輪
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要な市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要な投資の分析
- 主要な成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
マイコプラズマ検査の世界市場：用途別
- 市場概要
- 細胞株試験
- ウイルス検査
- エンドオブプロダクション細胞のテスト
- その他
マイコプラズマ検査の世界市場：最終用途別
- 市場概要
- 学術研究機関
- 細胞バンク
- 契約調査機関
- 製薬・バイオテクノロジー企業
- その他
マイコプラズマ検査の世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要な市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Merck KGaA（Germany）
- Thermo Fisher Scientific Inc.（US）
- Lonza Group Ltd.（Switzerland）
- Sartorius AG（Germany）
- PromoCell GmbH（Germany）
- American Type Culture Collection（ATCC）（US）
- Agilent Technologies, Inc.（US）
- Bionique Testing Laboratories, Inc.（US）
- Biological Industries Israel Beit Haemek Ltd.（Israel）
- Charles River Laboratories International, Inc.（US）
- Creative Bioarray（US）
- InvivoGen（US）
- Minerva Biolabs GmbH（Germany）
- Biological Industries US, Inc.（US）
- Norgen Biotek Corp.（Canada）
- Novacyt Group（UK）
- Mycoplasma Experience（France）
- Genscript Biotech Corporation（China）
- GeneCopoeia, Inc.（US）
- Jena Bioscience GmbH（Germany）
Global Mycoplasma Testing Market size was valued at USD 298.91 million in 2022 and is poised to grow from USD 340.76 million in 2023 to USD 972.04 million by 2031, growing at a CAGR of 14% during the forecast period (2024-2031).
Providing dependable, accurate, and effective instruments and services for identifying and averting Mycoplasma contamination in many contexts is the aim of the mycoplasma testing market. The market includes a wide range of goods, such as instruments, software, reagents, kits, and testing, in addition to laboratory services including consulting, testing, and validation. Numerous industries, including biotechnology, pharmaceuticals, academic research, and clinical diagnostics, are served by the mycoplasma testing market. The market for mycoplasma testing is propelled by multiple causes, such as the escalating need for cell-based therapies and biopharmaceuticals, the expanding consciousness about the potential hazards and repercussions of mycoplasma contamination, and the introduction of sophisticated technologies and platforms for mycoplasma testing. Furthermore, there is a growing need for more reliable and effective testing solutions due to the tightening and standardization of regulatory criteria and norms around mycoplasma testing. The market for mycoplasma testing is also constrained by a number of variables, including the high price of testing goods and services, the lack of harmonization and consistency in testing protocols, and the scarcity of infrastructure and qualified labor for mycoplasma testing. The market for mycoplasma testing also has to contend with a number of obstacles, including the requirement for ongoing innovation and enhancement of testing goods and services in order to meet changing consumer and regulatory demands. Additionally, the market must deal with the problems of cross-reactivity with other pollutants, false-positive and false-negative results, and the possibility of genetic variability and adaptation of mycoplasma strains.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mycoplasma Testing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the Market size includes the following details: The key players in the Market were identified through secondary research, and their Market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top Market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Mycoplasma Testing Market Segmental Analysis
The global mycoplasma testing market is segmented on the application, end-use and region. By application, the market is segmented into cell line testing, virus testing, end of production cells testing, others. By end-use, the market is segmented into academic research institutes, cell banks, contract research organizations, pharmaceutical & biotechnology companies, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Drivers of the Global Mycoplasma Testing Market
The market for Mycoplasma testing is being driven by the increasing need for cell-based treatments and biopharmaceuticals. To guarantee the safety and effectiveness of these products and therapies, premium cells free of Mycoplasma contamination are needed.
Restraints in the Global Mycoplasma Testing Market
Many clients may find the high expense of mycoplasma testing goods and services to be a major deterrent, particularly in developing nations or environments with limited resources. The type of test utilized, the sample's complexity, and the test's sensitivity and specificity can all affect how much a mycoplasma test costs. Certain sophisticated testing techniques, such high-throughput sequencing or PCR-based assays, can be quite costly, rendering them unaffordable for certain clients.
Market Trends of the Global Mycoplasma Testing Market
Modern platforms and technologies, like PCR-based assays, flow cytometry, and nucleic acid sequencing, are emerging in the mycoplasma testing sector. These tools provide improved speed, sensitivity, and specificity over the conventional culture-based approaches.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Mycoplasma Testing Market by Application
- Market Overview
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- and Others
Global Mycoplasma Testing Market by End-Use
- Market Overview
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- and Others
Global Mycoplasma Testing Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PromoCell GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- American Type Culture Collection (ATCC) (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bionique Testing Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biological Industries Israel Beit Haemek Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Charles River Laboratories International, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Creative Bioarray (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- InvivoGen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Minerva Biolabs GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biological Industries US, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Norgen Biotek Corp. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novacyt Group (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mycoplasma Experience (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genscript Biotech Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GeneCopoeia, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jena Bioscience GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
